Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-599626
panHer · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Phase 1 MTD Study | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-599626 | DRUG | - |
| panHer | DRUG | Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached. |
Inclusion Criteria: * Signed written informed consent * Available for periodic follow-up * Life expectancy of at least 3 months * ECOG performance status score 0-1 * Histologic or cytologic diagnosis of a primary malignancy of breast, ovarian, bladder, gastric, non small cell lung or colon origin *...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
panHer is an investigational small molecule developed for the treatment of cancer. It was studied in patients with advanced solid malignancies, including metastatic disease, in a Phase 1 trial. It is not an approved therapy and remains in clinical development.
panHer is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 study of the compound in patients with advanced solid tumors.
panHer is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The completed study enrolled 60 patients with advanced solid malignancies and metastatic disease.
panHer has been evaluated in one completed Phase 1 trial, NCT00095537, titled BMS-599626 in Patients With Advanced Solid Malignancies. The study enrolled 60 adults aged 18 years and older in the United States and included a randomized design.
No. panHer is an investigational agent and has not been approved by the FDA. It has completed only a single Phase 1 trial in patients with advanced solid malignancies, so it remains in early clinical development for cancer.